MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • GEG Collaborates with DSAL and Local Organizations to Support the Professional Growth of Local Team Members

  • 1 in 14 residents has diabetes, SSM survey finds

  • Grand Prix opens with citywide cultural festival

  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • 39 land parcels earmarked for temporary public facilities

  • Grand Prix road closures to disrupt 51 bus routes

Opinion
Home›Opinion›World Views | Merck, Samsung accelerate a biosimilar drug price war

World Views | Merck, Samsung accelerate a biosimilar drug price war

By -
Wednesday, July 26, 2017
149
0

Well, that was a short honeymoon.  Back in November, when Pfizer Inc. launched its biosimilar – a generic version of a drug made with living cells – of Johnson & Johnson’s blockbuster inflammation drug Remicade, it priced the copy at just a 15 percent discount to the original’s list price. That disappointed anyone hoping biosimilars would bring a golden age of cheaper drugs. But it was also relatively friendly, as far as legally risky launches of copycat versions of flagship products go. It left J&J not having to fear losing too much in the way of sales, while giving Pfizer a healthy margin on its own sales.

But then Merck & Co. and Samsung Bioepis had to ruin the party on Monday, by launching a competing biosimilar – developed by the Samsung biotech unit and marketed by Merck in the U.S. – at a 35 percent discount to Remicade’s list price. 

This has effects beyond Remicade and its imitators. The biosimilar market is developing just as Allergan PLC CEO Brent Saunders predicted: As more versions of drugs hit the market, prices will rapidly drop, eating away at the profits of everybody involved.

Pfizer will likely be forced to match Merck and Samsung price cut. And then J&J will have a harder time getting people to pick its more- expensive original, which is expected to be J&J’s largest medicine through 2019.

Just look at what happened to Merck, which has a license to sell branded Remicade in Europe. Since biosimilars first hit the market there about three years ago, Remicade sales are down more than 60 percent from their peak. 

Analysts expect J&J’s sales to decline at a slower rate than that – about 32 percent from 2016 to 2019 – but they may be too optimistic. Yes, there are still some regulatory barriers to broad biosimilar uptake in the U.S. Then again, Remicade didn’t face two biosimilar launches in Europe in such a short time period. And insurers eager to cut costs, along with Merck and Samsung’s massive biosimilar price cut, should smooth patient uptake of Remicade competitors.

Along with other firms that make competing inflammation drugs – such as Amgen Inc.’s Enbrel and AbbVie Inc.’s Humira – biosimilar manufacturers should be feeling antsy, too.

Firms that make biosimilars like these drugs because they have high margins and pricing relative to traditional generics. But they are also more expensive to develop and bring to market.

Merck and Samsung are setting a scary precedent by more than doubling Pfizer’s discount in the lucrative U.S. market despite being only the second biosimilar to arrive there. That discount comes before large insurers and pharmacy benefit managers have started negotiating their own price breaks – the total cut may be even larger. 

Meanwhile, a huge crop of biosimilars is on the way for a variety of drugs, threatening an even bigger race to the pricing bottom. Want a scary precedent for the industry? Look to Norway, where a Remicade biosimilar is available at a nearly 70 percent discount to the original.

Pfizer’s brief period of having the only U.S.- approved Remicade biosimilar will likely be the norm in the future, as the FDA gets quicker about approving biosimilars. The agency is gaining experience in evaluating them, and new chairman Scott Gottlieb has made bringing more competition to expensive medicines a priority. Biosimilars are a logical place to start.

Eventually there may not even be a short honeymoon period of modest discounts for new biosimilars before cutthroat competition starts. This is likely not what firms anticipated when they committed years and big budgets to breaking into this market.

The big positive of all this, of course, is that lower prices mean many more patients will get access to these medicines. But the biosimilar pie may be smaller and split more ways than some drugmakers expected.  Max Nisen, Bloomberg

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

Wednesday, July 26, 2017 – edition no. ...

Next Article

Met exhibit looks at Japan’s fine craft ...

Related articles More from author

  • OpinionThe Conversation

    What the tattoos of World Cup players say about their love, life and religious beliefs 

    Wednesday, June 24, 2026
    By -
  • Opinion

    Covid devastates Macau casinos

    Wednesday, August 10, 2022
    By -
  • Opinion

    World Views | Chinese investors are swimming in a giant bubble

    Tuesday, June 23, 2015
    By -
  • Multipolar WorldOpinion

    Energy transition, wishful thinking, and the erosion of democracy

    Tuesday, December 20, 2022
    By -
  • Opinion

    Rear Window | Pride that blinds

    Monday, October 28, 2019
    By Severo Portela
  • Shuli-Ren,-Bloomberg
    Business ViewsOpinion

    A Chinese Alternative to the Magnificent Seven has arrived

    Thursday, February 27, 2025
    By -

  • World

    Russia says Ukraine sent drones to hit Putin; Kyiv denies it

  • World

    Israel | Netanyahu negotiating plea deal in corruption trial

  • Opinion

    China Daily | ‘Democracy summit’ a wimpy show of US, Taiwan island

DAILY EDITION

Monday, November 16, 2026 – edition no. 5075
Monday, November 16, 2026 – edition no. 5075

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Monday, November 16, 2026

    GEG Collaborates with DSAL and Local Organizations to Support the Professional Growth of Local Team Members

  • Monday, November 16, 2026

    1 in 14 residents has diabetes, SSM survey finds

  • Monday, November 16, 2026

    Grand Prix opens with citywide cultural festival

  • Monday, November 16, 2026

    Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • Monday, November 16, 2026

    39 land parcels earmarked for temporary public facilities

  • Monday, November 16, 2026

    Grand Prix road closures to disrupt 51 bus routes

  • Monday, November 16, 2026

    Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

  • Monday, November 16, 2026

    Creative industries need creative people

  • Monday, November 16, 2026

    Strictly upholding the bottom line of the rule of law and safeguarding its core values

  • Monday, November 16, 2026

    Strictly adhering to statutory procedures; Safeguarding national security interests

Extra Times

Extra TimesHeadlinesTaste of Edesia

Three chefs. One horizon. Six Michelin stars

There are moments when separate culinary philosophies align so precisely that the result transcends mere menu-making. At Chef Tam’s Seasons, Wynn Palace, three two-Michelin-starred titans—each ranked among Asia’s 50 Best ...
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • The Twelve25 × La Vie exchange

    By -
    Friday, November 13, 2026
  • A fiery milestone: Feng Wei Ju’s 20th anniversary tribute to Starworld Macau

    By Irene Sam, MDT
    Friday, November 6, 2026
  • In ‘I Play Rocky,’ a middleweight crowd-pleaser about the making of a classic

    By MDT/AP
    Friday, November 6, 2026
  • Recent

  • Popular

  • GEG Collaborates with DSAL and Local Organizations to Support the Professional Growth of Local Team ...

    By GEG PR
    Monday, November 16, 2026
  • 1 in 14 residents has diabetes, SSM survey finds

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Grand Prix opens with citywide cultural festival

    By Renato Marques, MDT
    Monday, November 16, 2026
  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • 39 land parcels earmarked for temporary public facilities

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • Grand Prix road closures to disrupt 51 bus routes

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

    By -
    Monday, November 16, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d